Artract Medical is a technology company.
Artract Medical has raised $100K across 1 funding round.
Artract Medical has raised $100K in total across 1 funding round.
Artract Medical has raised $100K in total across 1 funding round.
Artract Medical's investors include New Age Ventures.
Artract Medical is a technology company that develops a passive hemodynamic assist device specifically designed to treat Heart Failure with preserved Ejection Fraction (HFpEF), a condition affecting over half of heart failure patients characterized by normal systolic function but impaired ventricular filling. Their device is implanted percutaneously and aims to address a significant unmet medical need, as no effective medical device currently exists for HFpEF therapy. Artract Medical serves patients suffering from this complex cardiac syndrome, improving their quality of life by alleviating symptoms such as breathlessness and fatigue. The company is positioned in the medical device sector with a focus on innovative cardiovascular solutions, showing growth momentum through its pioneering approach to a condition with poor survival rates[3].
Artract Medical was founded by Dr. Wolfgang Götz, who also serves as Chairman of the Board, alongside other experienced entrepreneurs including Markus Frank (CFO) and Volker Berl (Executive Director). The idea emerged from the recognition of the lack of effective device-based therapies for HFpEF, a growing clinical challenge. Early traction includes the development and clinical advancement of their passive hemodynamic assist device, which is designed to improve patient outcomes in a condition where traditional heart failure treatments have limited efficacy. The company’s leadership team brings a blend of medical expertise and entrepreneurial experience, driving the evolution of their technology and market approach[3].
Artract Medical rides the trend of increasing demand for innovative cardiovascular medical devices that improve patient outcomes in chronic diseases. The timing is critical as HFpEF prevalence rises with aging populations and better diagnosis, yet therapeutic options remain limited. Market forces favor companies that can deliver minimally invasive, effective solutions for complex cardiac conditions. By focusing on HFpEF, Artract Medical contributes to expanding the medical device ecosystem beyond traditional heart failure therapies, potentially influencing clinical practice and stimulating further innovation in hemodynamic assist technologies[3][4].
Looking ahead, Artract Medical is poised to advance clinical trials and regulatory approvals to bring its device to market, potentially transforming HFpEF treatment. Trends such as aging demographics, increased heart failure prevalence, and demand for less invasive therapies will shape their journey. Their influence may grow as they establish clinical efficacy and expand adoption, possibly inspiring new device innovations for heart failure subtypes. Continued leadership in this niche could position Artract Medical as a key player in cardiovascular medical technology, addressing a critical unmet need with significant patient impact[3][4].
Artract Medical has raised $100K across 1 funding round. Most recently, it raised $100K Seed in May 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2021 | $100K Seed | New Age Ventures |